NeuroSense Therapeutics (NRSN)
(Delayed Data from NSDQ)
$1.12 USD
-0.03 (-2.61%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.14 +0.02 (1.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for NeuroSense Therapeutics Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 7 | 11 | 1 | 1 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 3 | 7 | 11 | 1 | 1 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 3 | 8 | 11 | 1 | 1 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 1 | 1 | 0 | 0 |
Total Current Liabilities | 3 | 2 | 1 | 0 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 0 | 2 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 2 | 2 | 0 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 30 | 26 | 17 | 5 | 3 |
Retained Earnings | -32 | -21 | -8 | -4 | -2 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -2 | 6 | 9 | 1 | 1 |
Total Liabilities & Shareholder's Equity | 3 | 8 | 11 | 1 | 1 |
Total Common Equity | -2 | 6 | 9 | 1 | 1 |
Shares Outstanding | 13.60 | 10.90 | 10.90 | NA | NA |
Book Value Per Share | -0.14 | 0.52 | 0.83 | 0.00 | 0.00 |
Fiscal Year End for NeuroSense Therapeutics Ltd falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 3 | 5 | 7 | 4 |
Receivables | NA | 0 | 0 | 0 | 1 |
Notes Receivable | NA | 0 | NA | NA | 0 |
Inventories | NA | 0 | NA | NA | 0 |
Other Current Assets | NA | 0 | NA | NA | 0 |
Total Current Assets | NA | 3 | 5 | 8 | 5 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | NA | NA | 0 |
Deferred Charges | NA | 0 | NA | NA | 0 |
Intangibles | NA | 0 | NA | NA | 0 |
Deposits & Other Assets | NA | 0 | NA | NA | 0 |
Total Assets | NA | 3 | 5 | 8 | 5 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | NA | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 0 |
Current Portion Long-Term Debt | NA | 0 | NA | NA | 0 |
Current Portion Capital Leases | NA | 0 | NA | NA | 0 |
Accrued Expenses | NA | 0 | NA | NA | 0 |
Income Taxes Payable | NA | 0 | NA | NA | 0 |
Other Current Liabilities | NA | 2 | 2 | 2 | 1 |
Total Current Liabilities | NA | 3 | 3 | 3 | 2 |
Mortgages | NA | 0 | NA | NA | 0 |
Deferred Taxes/Income | NA | 0 | NA | NA | 0 |
Convertible Debt | NA | 0 | NA | NA | 0 |
Long-Term Debt | NA | 0 | NA | NA | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 6 | 1 | |
Minority Interest (Liabilities) | NA | 0 | NA | NA | 0 |
Total Liabilities | NA | 5 | 6 | 9 | 2 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | NA | 0 |
Common Stock (Par) | NA | 0 | NA | NA | 0 |
Capital Surplus | NA | 30 | 29 | 28 | 28 |
Retained Earnings | NA | -32 | -29 | -30 | -25 |
Other Equity | NA | 0 | NA | NA | 0 |
Treasury Stock | NA | 0 | NA | NA | 0 |
Total Shareholder's Equity | NA | -2 | 0 | -2 | 3 |
Total Liabilities & Shareholder's Equity | NA | 3 | 5 | 8 | 5 |
Total Common Equity | 0 | -2 | 99,999 | 99,997 | 3 |
Shares Outstanding | 13.60 | 13.60 | 13.60 | 10.90 | 10.90 |
Book Value Per Share | 0.00 | -0.14 | 7,352.85 | 9,174.08 | 0.27 |